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1. ABSTRACT 
 
Despite the advent of a considerable number of new antibiotics, treatment of intracellular pathogens still represents a 
major pharmaceutical challenge. The antibiotic concentration in those specialized niches are often subtherapeutic, for which high 
doses of antibiotics must often be used. This is not only costly but may also increase localized or systemic side effects. There is 
therefore an urgent need for materials and methods to enable clinicians to achieve therapeutically effective intracellular 
concentration of those antibiotics which show good efficiency in vitro. In this setting, the possible use of drug delivery systems 
(DDS) loaded with antibiotics that exhibit a high in vitro bactericidal activity deserves to be considered. Entrapping or 
encapsulating the drug within a delivery system provides a greater control of the pharmacokinetic behavior of the active 
molecule. This more efficient use of antibiotics may diminish their drawbacks and provide the basis for shortening the current 
time required by classical treatments. This review will focus on the role of DDS as a potential tool against intracellular bacteria. 
 
2. INTRODUCTION 
 
The chemotherapy of infections caused by bacteria that reside intracellularly presents a number of unusual challenges. 
On the one hand, several bacteria have found the way to produce a “silent” infection inside the cells and to escape from their 
bactericidal mechanisms. Thus, in these situations, cells are not only incompetent to eradicate the intracellular bacteria but also 
may act as reservoirs and contribute to the spreading of the infection to other cells and organs. Moreover, due to their 
intracellular location bacteria are protected from the attack of the immune system as well as from the action of the antibiotics 
present in the extracellular milieu. Thus, although a wide variety of antibiotics have been found to be active against isolated 
bacteria, disappointing results are obtained against these pathogens in the intracellular environment (1). On the other hand, since 
antibiotic treatment of intracellular infections is not always successful, long-lasting combined therapeutic regimens are usually 
needed. However, although combined therapies are more effective than single ones, their fulfilment becomes more difficult for 
patients and this can lead to a poor patient compliance and abandoning of the antibiotic treatment. Taken together, all these 
factors may contribute to the occurrence of relapses after treatment.  
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In this context, the current review will focus on the potential utility of antibiotic-containing DDS in the treatment of 
intracellular infections. These DDS can deliver antimicrobial agents and target intracellular sites of infection, thereby helping to 
increase the therapeutic index of antimicrobials in intracellular niches, while avoiding problems associated with administering 
high doses of antibiotics systemically.   
 
3. LIFESTYLES OF INTRACELLULAR BACTERIAL PATHOGENS 
 
A significant niche to be considered in the area of infectious diseases is the intracellular milieu of the professional 
phagocytes. Paradoxically, these specialized cells tailored to kill and digest the ingested material are a satisfying habitat for 
bacterial pathogens such as Listeria, Brucella, Mycobacterium or Salmonella. The strong evolutionary pressure for overcoming 
the lethal immune system challenge has resulted in a diverse repertoire of microbial strategies to create a safe replicative niche. 
Intracellular (obligate or facultative) pathogens present different virulence factors that will modulate their intracellular fate (2).  
 
Figure 1 shows the classic action of the phagocyte to kill and degrade the ingested bacteria. The endocytic pathway is 
used for the uptake of nutrients and recycling of proteins used in the secretory pathway, among other functions. Phagosomes 
containing ingested bacteria fuse with early endosomes, acquiring markers that confer on phagosomes properties normally 
assigned to early endosomes, including the ability to fuse with other endocytic organelles (3, 4). They fuse sequentially with 
endosomes of increasing age or maturation level (late endosomes and lysosomes) acquiring new markers and a more acidic 
environment (pH 5.5). Changes in the phospholipid composition is also observed during phagosome maturation; while early 
phagosomes are enriched with phosphatidylcholine, late phagosomes are preferentially enriched with sphingomyelin (5). 
Altogether, these changes contribute to the formation of the phagolysosome, an acidic compartment displaying not only the harsh 
and lytic environment needed to kill and degrade the ingested material (4), but also a harsh milieu to maintain the bioactivity of 
many drugs. Intracellular bacteria have found ways to divert their usual trafficking from early endosomes towards these 
inhospitable phagolysosomes. Pathogens can thus escape from the endocytic vacuole to the cytoplasm, live within the 
phagolysosome, or create their own privileged niche (Table 1) (6-22). Regardless of the means by which this is achieved, 
pathogens can survive and replicate undetected within the protected niche of the host cell. Several pathogens represent 
paradigmatic models for intracellular survival mechanisms.   
 
3.1. Lysis of the intracellular vacuole and escape to the cytosol 
Listeria and Shigella are examples of pathogens which can escape from the phagocytic vacuole avoiding exposure to 
the degradative compartments of the endocytic route, and therefore are finally found at the neutral pH and nutrient-rich host 
cytosol. Listeria monocytogenes has the ability to enter and survive into both phagocytic and non-phagocytic cells and it invades 
the cytosol thanks to a pore-forming hemolysin (listeriolysin O) and some phospholipases (a phosphatidylinositol-specific 
phospholipase C and a broad-spectrum phospholipase C) (23). Listeriolysin O forms pores in the vacuole membrane allowing the 
release of the phospholipases which cause the disruption of this Listeria-containing vacuole membrane. Once in the cytosol the 
bacterium induces the nucleation of host actin filaments and the formation of an actin tail that is able to push the bacterium into 
the neighboring cells, in which it reinitiates this lifecycle (7). In the case of Shigella flexneri a cytotoxin lyses the membrane of 
the phagosome and allows it to escape to the cytosol. Like Listeria, Shigella exploits the host actin polymerization machinery and 
induces the formation of actin-rich comet tails by means of a protein called IcsA (24). 
 
3.2. Arrest of phagosome maturation 
Other pathogenic bacteria such as Salmonella and Mycobacterium arrest the maturation of the phagosome at specific 
stages of the phago-lysosomal route and evolve into an intracellular life cycle involving prevention of phagosome-lysosome 
fusion. As a consequence, the pH of the final localization of the bacteria is close to neutrality. Salmonella typhimurium 
transiently acquires early endosome markers but it has developed mechanisms to modulate the redistribution of endosomal and 
lysosomal markers and it seems that it may modulate the expression of vacuolar ATPases to generate a relatively less acidic 
phagosomal compartment (25).  
 
Professional phagocytes are the preferred targets of Mycobacterium spp. Soon after its phagocytosis, Mycobacterium-
containing vacuoles acquire many of the typical early endosomal markers but not late endosomal/lysosomal ones, suggesting that 
Mycobacterium arrest maturation before the formation of late phagosomes (12). The active retention of a phagosomal coat 
protein termed TACO (tryptophan and aspartate containing coat protein) may play an important role in the prevention of 
phagosome maturation and its consequent fusion with lysosomes (26). As a result, bacteria ensure their survival, but remain in a 
dormant state producing a latent infection which can last for years. 
  
3.3. Segregation from the endocytic route 
Chlamydia, Legionella and Brucella phagosomes segregate from the endocytic route to create a suitable niche for 
intracellular replication. Chlamydia spp. represents one of the most extreme cases. The chlamydiae are obligate intracellular 
pathogens that grow in cytoplasmic vesicles in a wide variety of host cells, including blood circulating monocytes and tissue 
macrophages. Chlamydia segregates from the endocytic pathway at a very early stage of development and inhabits membrane-
bound vacuoles termed inclusions. No marker of the endocytic route is accumulated on or within the inclusion (27). These 
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inclusions localize close to the Golgi network and fuse to exocytic vesicles containing sphingomyelin, which seems to be 
essential for the intracellular replication of Chlamydia (28). Furthermore, monocytes have been shown to support C. pneumoniae 
growth for several days, thus, they can act as carrier systems for the bacteria and spread the infection from the respiratory tract to 
other organs. 
 
Legionella pneumophila is a facultative intracellular pathogen that colonizes mainly alveolar macrophages. Vacuoles 
harboring L. pneumophila have also been shown not to acquire endosomal and lysosomal markers (29) but to recruit endoplasmic 
reticulum (ER)-derived vesicles, indicating that the bacteria reside in a compartment surrounded by ER until the monocytes lyse 
releasing the bacteria (30). Apparently, a type IV secretion system, the Dot–Icm secretion system, is used by the bacteria to 
modify the normal organelle trafficking, therefore preventing fusion with lysosomes and permitting L. pneumophila to establish 
itself within that unique ER-like compartment.  
 
Brucella spp. are facultative intracellular pathogens that infect and replicate inside the cells and organs or the 
mononuclear phagocytic system (MPS), mainly in the liver and the spleen. When they are captured by phagocytic cells, these 
organisms present an excellent model for escaping to a safe replicative niche subverting the regular phagosome maturation 
process. After ingestion the pathogens localizes in early phagosomes. Most of them are in vacuoles retaining late 
endosomal/lysosomal markers (LAMP-1 positive) and will eventually be killed. However, a few of these vacuoles avoid further 
fusions with lysosomes. Brucella lipopolysaccharide on the bacterial surface and cyclic beta-1,2-glucan have been proposed to 
play a role in the control of the phagosomal maturation (31). Cyclic beta-1,2-glucans, structurally related to cyclodextrins, can 
selectively extract and incorporate cholesterol, glycosylphophatidylinositol and ganglioside GM-1, which are essential for 
bacterial survival and replication, from lipid rafts to phagosomes. Whatever the case, those vacuoles that successfully evade 
lysosomal fusion are characterized by the progressive exclusion of LAMP-1 and are capable of interacting with ER exit sites. 
Subsequently, they fuse to ER to generate ER-derived replicative Brucella-containing vacuoles. In this case, the acidification of 
the Brucella-containing vacuole is a requisite to trafficking to the ER and subsequent intracellular replication of the bacteria (32).  
 
3.4. Life within acidic phagosomes 
Staphylococcus aureus is a ubiquitous bacterium that usually produces local infections which spreads to other tissues 
and organs. Although it has been considered to be an extracellular pathogen, it easily invades non-professional and professional 
phagocytes. S. aureus persists in the phagolysosomal compartment of phagocytic cells and under these conditions can survive 
several days before inducing their lysis (22). This particular localization of the bacterium seems to be the reason for the recurrent 
character of staphylococcal infections, as well as for the failures of clinical treatments using antibiotics that are active in vitro. 
 
Finally, as a new example of intracellular adaptation, the obligate intracellular Coxiella burnetii inhabits an acidified 
lysosomal-like compartment (18). It has been shown that after its entrance into human macrophages Coxiella adquires late 
endosomal-early lysosomal markers and resides in acidic vacuoles with pH 5, remaining metabolically active.  
 
4. ANTIBIOTIC TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS  
 
It seems clear that obtaining a high concentration of a given drug within the cells is not enough to achieve the 
eradication of intracellular bacteria. Intracellular pathogens, when inside cells, are not only protected from the extracellular 
environment (antibodies, complement, and even some antibiotics), but also these new physicochemical intracellular conditions 
induce strategic (structural and metabolic) changes, making them resistant to antibiotics that are active in vitro. Likewise, it 
should be stressed that the intracellular activity of antibiotics may also change. For instance, the bactericidal activity may be lost 
at the acidic pH of phagolysosomes or these drugs may not be able to access the host cell organelles, where the microorganism 
resides and replicates (see above). Therefore, the final encounter between the pathogen and the antibiotic may not be as 
successful as predicted by in vitro studies (1).  
 
In order for a treatment to be successful the antibiotic used must fulfill a series of criteria, including the ability to enter 
and be retained by the cell, the capacity to reach the intracellular target, and the display of activity in that peculiar environment 
where the bacteria reside.  
 
It has been recognized that a number of antibiotics do not efficiently penetrate cells, thereby achieving low intracellular 
concentrations. This is the case of beta-lactams and aminoglycosides. Beta-lactam antibiotics exert their antibacterial action by 
inhibiting the synthesis of peptidoglycan. Most beta-lactams are weak acid compounds that, although capable of crossing biologic 
membranes, do not accumulate within the cells, probably due both to the more acidic nature of the cell cytosol compared to the 
extracellular milieu and active antibiotic efflux pumps (33). However, it has been shown that the low accumulation of beta-
lactams in cells can be compensated by their good activity at acidic pH, conferring these drugs therapeutic potential in spite of 
their apparently unfavorable cellular pharmacokinetics (34). 
 
Aminoglycosides are antibiotics with broad antimicrobial activity, post-antibiotic effect and synergy with beta-lactam 
antibiotics. However, aminoglycosides show a limited intracellular activity compared to their strong bactericidal activity in an 
extracellular medium. These drugs diffuse very slowly and poorly through cell membranes due to their high hydrophilicity, but 
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they may be incorporated into macrophages using a fluid-phase pinocytosis process when applied at high concentrations and long 
incubation times. (35). In contrast to the beta-lactams, aminoglycosides are weakly basic, so after reaching the interior of the cell 
they are confined within the lysosomes, where the acidic pH may suppress their activity. This lack of activity has been related to 
the protonation of the molecule at acidic pH. Since aminoglycosides enter the bacteria by active transport, factors affecting this 
transport would reduce their antibacterial activity (36). Another important issue that limits the use of aminoglycosides is their 
well-known toxicity. The main adverse effect of aminoglycosides is nephrotoxicity, as a result of renal cortical accumulation, 
followed by ototoxicity and, to a lesser extent, neuromuscular blockade (37). The narrow therapeutic range between effective and 
toxic aminoglycoside levels prevents the use of high concentrations of these drugs. 
 
In contrast to the lack of accumulation within the cells reported for the antibiotics mentioned above, macrolides and 
quinolones present a high cellular accumulation but, nevertheless, there is not always a direct correlation between their 
accumulation and intracellular activity. Macrolides are weak organic bases that show a marked cell penetration and tissue 
accumulation, for which they occupy a prominent place in the treatment of infections caused by intracellular bacteria. Inside the 
cells macrolides distribute mainly to the cytosol and lysosomes where they are trapped by protonation. However, the final 
outcome depends on the macrolide used. Some studies have shown that azithromycin, for instance, may be essentially 
bacteriostatic against Listeria monocytogenes (35) and S. aureus (38), probably because their acidic pH environment decreases 
macrolides activity (39).  
 
Quinolones, another class of antibiotics that achieve high intracellular concentrations in both infected and non-infected 
cells, can diffuse to various subcellular compartments without associating with any specific cellular structure (40). The majority 
of quinolones are effective against intracellular bacteria as Legionella (41) and Listeria monocytogenes (35) but some of them 
show reduced activity at lower pH, which would explain the discrepancy between their extracellular and intracellular activities 
when treating pathogens that are localized within phagolysosomes (42). 
 
Furthermore, occasionally, treatment is made difficult due to the specific characteristics of the bacteria, e.g. the 
presence of metabolically silent or dormant bacteria within the host, which may not be susceptible to some antimicrobial agents. 
Bacteria in such a phase are much more tolerant to antibiotics than logarithmic phase organisms because they undergo a series of 
physiological or phenotypic changes that can block antibiotic targets (43). For example, an antibiotic that inhibits protein 
synthesis will have no effect when the intracellular bacteria are in a dormant stage. Beta-lactams exert their bactericidal activity 
on multiplying microorganisms (synthesis of peptidoglycan, but not the structure itself), so no effect will be expected if the 
bacteria do not replicate.  
 
Finally, it has been established that antimicrobial drugs can influence the interaction between microorganisms and 
phagocytes (44). Antibiotics in general have the ability to alter various functions of the antimicrobial activity of the phagocytic 
cells of the host. For example, gentamicin enhances the intracellular destruction of microorganisms by the macrophage (45), 
while the other aminoglycosides inhibit this ability (46). On the contrary, chemotaxis, oxidative burst or cytokine production are 
not affected by aminoglycosides. Finally, there are studies that indicate that this type of antibiotics does not influence the 
endocytic machinery, whereas other works suggest inhibitory effects (47). 
 
5. ANTIBIOTIC ENCAPSULATION IN DRUG DELIVERY SYSTEMS  
 
In spite of the emergence of new antibiotics, the treatment of intracellular infections remains unsolved. The main 
challenge for intracellular chemotherapy is to design and develop a carrier system for antibiotics that could be efficiently 
endocytosed by phagocytic cells and, once inside the cells, capable of releasing the drug. In this sense, polymeric and lipidic 
DDS are well suited as vehicles for the delivery of antimicrobial agents because they usually provide a sustained drug release 
effect, minimize the toxicity associated with the encapsulated drugs and increase the overall drug efficacy. Moreover, DDS 
protect the incorporated drug from premature immunological and enzymatic attacks and, in some cases, they act synergistically 
with cellular bactericidal mechanisms (48).  
 
5.1. Liposomes 
Since their discovery in the early 1960s, liposomes have been one of the most extensively studied drug carriers. They 
are spherical vesicles of one or several concentric lipid bilayers, usually composed of phospholipids and cholesterol, enclosing 
aqueous compartments (49). Moreover, due to their similarity to biological membranes they present low toxicity and 
immunogenicity. Liposomes are of interest mainly because of their structural versatility and the possibility of entrapping drugs of 
different size and solubility properties. Depending on the method used for their preparation, liposomes of different sizes and 
number of lamellae can be obtained. Based on these parameters liposomes can be classified into small unilamellar vesicles 
(SUV), large unilamellar vesicles (LUV) and small plurilamellar vesicles (SPLV). Moreover, liposomes are able to entrap both 
hydrophilic and hydrophobic compounds. Water-soluble compounds are located in the aqueous spaces while lipid-soluble ones 
are bound or incorporated into the lipid membrane.  
 
When administered intravenously liposomes are rapidly removed by the phagocytic cells of the MPS (50), especially 
by macrophages in the liver (Kupffer cells) and spleen. This is one of the reasons which have lead to the study of the applications 
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of liposomes in the treatment of intracellular infections (51). However, the general use of liposomes as DDS has been hindered 
by several issues, the most important being the stability of liposomes after their administration. After intravenous administration 
liposomes are opsonized and exposed to the destabilizing interaction of certain blood constituents, especially lipoproteins. It has 
been suggested that upon contact between lipoproteins and liposomes, lipoproteins can remove phospholipids from the lipidic 
structure of the liposomes, living pores through which the content of the liposome is released (52). The grade of destruction of 
liposomes depends mainly on the type and composition of these vesicles. For instance, SUV composed exclusively of 
phosphatidylcholine are rapidly disrupted in the serum and lipids from the liposome are transferred to the lipoproteins. 
Conversely, the incorporation of cholesterol to the formulation can partially inhibit this disintegration (53). Therefore, it seems 
necessary to be careful in the choice of the liposome components for the successful design and development of liposome-based 
therapies.  
 
5.1.1. Uptake of liposomes by mononuclear phagocytic system cells 
Liposomes are mainly taken up by cells by means of endocytosis. However, fusion processes between liposomes and 
the cell membrane might also be involved in liposome uptake. The internalization of liposomes into phagocytic cells takes place 
following different steps: stable adsorption to the cell membrane, liposome uptake by an energy-dependent mechanism, the 
fusion with the lysosomes and degradation of the liposomes by the action of lysosomal enzymes releasing their content (Figure 2) 
(50). Among these, the first step seems to be the limiting one for liposome internalization, since a stable adsorption of the 
liposome to the cell surface will further facilitate its uptake. However, the extent of liposome adsorption and subsequent 
internalization depends on their physicochemical properties.  
 
Allen et al. studied the effect of the physicochemical properties of liposomes on the uptake by murine macrophages and 
they concluded that small and negatively charged liposomes were the ones most efficiently internalized (54). It seems that the 
negative charge can enhance the binding of liposomes to macrophages and promote their phagocytosis. Consistent with this, 
some authors have observed that negatively charged liposomes are internalized slightly more efficiently than neutral liposomes 
by murine macrophages, and to a greater extent than positively charged liposomes (55). However, it was also found that 
internalization was higher for antibody-coated liposomes than for non-coated liposomes, probably because in this case the uptake 
occurs by specific Fc receptor-mediated endocytosis. In addition, this type of coating apparently protects liposomes from cell 
surface-induced leakage by preventing close contact between the liposome and the cell surface. 
 
Cholesterol may also play an important role in liposome internalization. It has been suggested that the incorporation of 
cholesterol into liposomes may change the distribution of phospholipids in the membrane rendering phagocytosis more difficult 
(56). So, although cholesterol concentrations above 50% give optimal stability to liposomes in the presence of serum 
lipoproteins, a lesser amount of cholesterol would be preferable to provide sufficient liposome stability without compromising 
capture by phagocytic cells (57). 
 
Nevertheless, as stated above, liposomes are finally found at the lysosomal compartment,hence this strategy seems to 
be useful to fight bacteria that reside in lysosomes. Conversely, when the bacteria localize within other subcellular compartments 
the final encounter between the pathogen and the drug may be impaired. Different formulation strategies have been developed to 
solve this problem, including the preparation of pH-sensitive liposomes, which have the ability to escape from the endosomal 
compartment and release the encapsulated active compound in the cell cytoplasm. 
 
5.1.2. Intracellular destination of pH sensitive liposomes 
pH sensitive liposomes are stable at neutral pH but are destabilized at mildly acidic pH delivering the encapsulated 
material into the cell cytoplasm. There are two main categories of these liposomes: intrinsically pH-sensitive liposomes and those 
which utilize an external non-lipid trigger. In general, it is assumed that pH-sensitive liposomes are taken up more efficiently 
than pH-insensitive liposomes (58). After binding to the cell surface, liposomes enter cells via endocytosis and then are delivered 
into endosomes, where they encounter a more acidic environment than the extracellular milieu. This type of liposomes presents 
membranes that have been designed to destabilize and/or fuse with the endosomal membrane when the pH value drops, resulting 
in the release of the active compound to the cytoplasm prior to arrival in the lysosomes (Figure 2). Dioleoyl 
phosphatidylethanolamine (DOPE) and weakly acidic amphiphilies have been widely used to confer intrinsic pH-sensitivity to 
liposomes (58, 59). At physiological pH, amphiphilies possess negative charges that stabilize the lipidic bilayer structure. 
However, as the pH decreases (as it happens in endosomes), the head group of amphiphilies become protonated and 
phosphatidylethanolamine molecules revert from a bilayer phase to a non-bilayer phase, resulting in liposomal destabilization. 
Another strategy for endosomal escape of the pH-sensitive liposomes is the addition of proteins or peptides that exhibit 
membrane lytic or fusion properties at acidic pH. For example, the listeriolysin O from Listeria monocytogenes has been studied 
for this purpose (60).  
 
As with conventional liposomes, the major limitation of pH-sensitive liposomes in vivo is their aggregation and 
instability in plasma, but this problem can be solved by adding polyethylene glycol to the formulation (59). This coating prevents 
interaction with blood constituents, leading to an increased stability in plasma and also to a lower recognition by circulating 
monocytes. 
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5.1.3. In vitro efficacy of liposome-assisted antibiotic treatment 
Several antibiotics have been encapsulated into liposomes to improve their interaction with phagocytic cells and obtain 
an intracellular accumulation (61). Most studies on liposome-encapsulated antibiotics have been performed in Mycobacterium-
infected cells. In this sense, liposome-entrapped quinolones and macrolides have shown to enhance the killing of intracellular M. 
avium complex (MAC). Encapsulating ofloxacin and clarithromycin into liposomes significantly increased the internalization and 
intracellular efficacy of the drugs against MAC in human macrophages (62). Thus, at day 4 following treatment liposome-
encapsulated antibiotics were able to reduce the number of colony forming units (CFU) by more than 0.93 log units and 0.4 logs, 
respectively, in comparison to free drugs. Similarly, liposome-encapsulation of azithromycin, rifabutin and clarithromycin 
significantly increased their delivery into macrophages and their antimycobacterial activity, compared to the same concentration 
of the free drugs (63). In these two studies, the addition of ethambutol to either the free or liposome-encapsulated drugs led to an 
enhancement of their activity.  
 
Azithromycin- and ciprofloxacin-containing liposomes presented 40-fold greater activity in murine macrophages 
harboring Mycobacterium avium  (64). Among the different ciprofloxacin formulations tested, a maximal cellular accumulation 
and antimycobacterial activity of ciprofloxacin was reached as the negative charge of the liposomes increased. The quinolone 
sparfloxacin has also been entrapped into liposomes in order to be used against MAC-infected J774 macrophages (65). However, 
the reduction of the intracellular bacteria was only slightly higher for the liposome-encapsulated antibiotic in comparison to its 
free form. In this case, the lack of a marked increase in the effectiveness of the liposomal form of sparfloxacin may be ascribed to 
its intrinsic lipophilic nature, which enables it to accumulate efficiently in macrophages.  
 
Aminoglycoside antibiotics have also been tested for their ability to reduce intracellular MAC (66). Liposomal 
streptomycin was more effective in the intracellular killing of bacteria than the free drug, achieving a reduction of 89.1% of the 
CFU with the higher dose used (50 mg/l). It was found that the unloaded liposomes reduced the infection by 0.2 log units at this 
lipid dose, suggesting that they could improve the antibacterial activity of the antibiotic. The same study also reports that 5 mg/l 
of ciprofloxacin-loaded liposomes produced a 50-fold reduction of the initial level of infection compared to the free drug. 
 
Resorcinomycin A is another type of antibiotic that has shown more effective intracellular activity against MAC when 
its liposomal form is used (67). Three days after treatment with a 50 mg/L dose of free and liposome-encapsulated antibiotic 
resulted in 62% and 93% of bacterial growth inhibition, respectively. Moreover, liposomal resorcinomycin A maintained its 
antimycobacterial activity for 7 days after treatment, while the activity of the free drug lasted for less than 3 days. 
 
 Liposomes containing aminoglycosides have also shown to enhance the killing of other intracellular bacteria. Vitas et 
al. found that at a 20 mg/L concentration positively-charged SPLV containing 30% cholesterol and gentamicin completely 
eradicated the Brucella abortus infection in murine macrophages (57). In contrast, the same vesicles with 50% cholesterol had a 
markedly lower intracellular activity, reducing the number of CFU by 0.84 log units compared to the untreated control group. 
Gentamicin has also been entrapped into pH-sensitive liposomes in order to be used against Salmonella typhimurium and Listeria 
monocytogenes (68). At an equivalent gentamicin dose, the liposomal carriers achieved and intracellular gentamicin 
concentration 21.5 times higher than the free drug, being those liposomes that included DOPE and N-succinyl-DOPE in the 
formulation the most effective. This antibacterial activity was especially greater against L. monocytogenes and a hemolysin-
expressing S. typhimurium, which resides in the cell cytoplasm, than against wild-type S. typhimurium, suggesting that the 
gentamicin released from pH-sensitive liposomes concentrates mainly in the cell cytoplasm. In another study, liposomes 
containing dihydrostreptomycin showed 40-fold higher activity against intracellular S. aureus in murine macrophages in 
comparison to the effect exerted by the drug solution and unloaded liposomes (69).  
   
The entrapment of the beta-lactam antibiotic, flucloxacillin, and rifampicin in liposomes also improved the intracellular 
activity of these antibiotics against S. aureus compared to the free drugs (70). The study was performed in phagocytes which had 
a decreased or lack of ability to produce reactive oxygen intermediates (ROI). The number of surviving bacteria after the 
treatment with liposome-encapsulated flucloxacillin and rifampicin was 5 and 2.5 times lower than when treated with the free 
drugs.  
 
 Finally, beta-lactam antibiotics have also been liposome-encapsulated in order to treat intracellular infections produced 
by Listeria monocytogenes. A 50 mg/L concentration of ampicillin entrapped in liposomes killed 90% of the intracellular bacteria 
after 6 h incubation (71). On the other hand, penicillin G-containing liposomes reduced the infection by more than 3 log units 
when 100 U/mL of entrapped penicillin G were added to the infected cell culture (72). 
 
5.2. Polymeric micro- and nanoparticles 
Microparticles and nanoparticles were developed as alternative systems to liposomes, to solve their stability problems 
during storage and after administration in biological fluids. This improved stability and the possibility of obtaining a modulable 
controlled release of the encapsulated drug are the main advantages of polymeric particles over liposomal carriers. Thanks to 
advances in techniques for microencapsulation and the development of new polymers, such vectors are currently the subject of an 
extensive research on the encapsulation of many active ingredients such as hormones, anticancer antigens and antibiotics (73).  
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In the last few decades several methods were developed to prepare polymeric micro- and nanoparticles (74). Some of 
the common methods used for polymeric particle formulation are emulsification-solvent removal (or solvent evaporation), phase 
separation (or coacervation), interfacial polymerization and spray-drying. The selection of a particular technique depends mostly 
on the physicochemical characteristics of the drug of interest. In general, the polymers used for drug encapsulation purposes can 
be broadly divided into two groups, depending on their nature: natural and synthetic polymers. Natural polymers (i.e. human or 
bovine serum albumin, gelatin, collagen, alginate, chitosan, hyoluronan, starch) are polymers derived from natural sources. Their 
lack of purity and homogeneity and the risk of disease transmission have led to a decrease in their use. On the other hand, 
synthetic biodegradable and biocompatible polymers (i.e. poly(a-hydroxyacids), polyanhydrides like poly(sebacic acid) and 
poly(fatty acid dimer-sebacic acid), are extensively used for the encapsulation of many drugs. Among these synthetic polymers, 
the aliphatic polyesters poly(lactic acid) (PLA), and copolymer poly(lactic co-glycolic acid) (PLGA) are the most widely 
investigated class of polymers with regard to toxicological and clinical data (75). PLA and PLGA are non-toxic, biocompatible 
and biodegradable polymers approved by the Food and Drug Administration for human consumption (76, 77).  
 
5.2.1. Endocytosis and the intracellular fate of polymeric particles used as drug delivery systems  
Phagocytic cells are programmed not only to recognize pathogens, but also to localize and readily internalize foreign 
materials such as, for instance, polymeric particles used as DDS (78). Upon their intravenous administration, the particles interact 
with blood cell constituents and are generally captured by the macrophages of the MPS, being rapidly cleared from the blood-
stream. This phenomenon is related to opsonization, which involves the adsorption of plasma proteins, complement components 
and factors among others. Therefore, this fact, which would be a disadvantage in the treatment of some infections, provides 
passive targeting to the interior of monocytes and turns polymeric particles into exceptional candidates for the treatment of 
intracellular infections that affect the MPS.  
 
As illustrated above in the context of pathogens, the first experimental observation concerning intracellular transport of 
polymer particles was the fact that there is also a wide variation in the reported rates of phagosome maturation depending on the 
particles used (5, 79). The receptors or mechanisms of entry used during phagocytosis undoubtedly have major consequences on 
the biochemical nature of the nascent phagosomes (80). Namely, the physico-chemical parameters of the particles, such as size 
and surface hydrophobicity, determine some of the characteristics of the initial endosomal compartment (81). Further fusions 
with other endocytic vesicles and recruitment of various proteins from the cytosol influence particle trafficking along the 
phagolysosome pathway (3, 81) (Figure 3). However, the exact mechanism mediating the cellular uptake of particles and the 
advantages of specific sizes and surface properties of these DDS are just beginning to be understood. 
 
It is generally assumed that hydrophobic particles are more easily phagocytosed than hydrophilic ones by forming 
hydrophobic interaction with the cell surface (82). However, it has been shown that 1 μm-sized hydrophobic latex beads remain 
associated with early endosomes but do not fuse with lysosomes, finally being found in a relatively neutral environment (pH 6.0 
to 6.8). It seems that the tight apposition displayed with regard to the phagosome membrane prevents phagosome from its 
maturation, which is similar to the process observed with Mycobacterium to inhibit phagosome-lysosome fusion (83). On the 
other hand, hydrophilic particles are degraded at a faster rate upon the phagosome maturation into phagolysosomes. These 
particles are then found in the more acidic microenvironment typical of matured phagosomes (pH 4.6 to 5.1) (81). 
 
According to the size, Koval et al. (84) found that particles presenting a size below 1 μm are internalized by clathrin-
mediated endocytosis. Conversely, as the size of the particles increases, the uptake process becomes more clathrin-independent. 
Thus, for particles with a diameter of 1 μm or above, internalization occurs by phagocytosis after the formation of actin-coated 
invaginations in the macrophage membrane. In this study it was also observed that the mechanism of entry further influenced 
particle behavior inside the cell. Following their uptake, micrometric-range latex beads were quickly delivered to lysosomes 
while particles of smaller size showed a delayed delivery to lysosomes. Once there, it is expected that drug delivery particles can 
be degraded and the encapsulated drug released.  
 
Thus, in general, the more a particle is diverted from endocytic trafficking into phagolysosomes, the more slowly its 
contents are degraded. This behavior could be exploited to increase the half-life of therapeutic molecules. 
 
5.2.2. Synergy of polymeric particles with cellular bactericidal mechanisms 
Another point to be considered regarding the treatment of intracellular infections is the synergy of the polymeric 
particles with the bactericidal mechanisms of the phagocyte. The stimulation of the intracellular ROI may act synergistically with 
the antibiotic activity to kill intracellular bacteria, thus increasing treatment efficiency. For example, Lecároz et al. studied the 
effect of different PLGA polymers (PLGA 502H and 752H) on the characteristics of gentamicin-containing microparticles (85). 
The main difference between these two polymers is the lactide/glycolide ratio, being 50:50 for the copolymer 502H and 75:25 for 
752H. In addition, the copolymer 752H has a higher molecular weight and is more hydrophobic compared to 502H. These 
authors found that microparticles of uncapped PLGA 502H (free -OH and COOH groups) with hydrophilic end-groups stimulate 
the oxidative burst of macrophages in a more efficient way (measure of general cell activation) (86). However, the phagocytosis 
of microparticles may not correlate with the activation of the cells. Overall, the phagocytosis of microparticles depends mainly on 
the hydrophilicity of the polymer, whereas it is the presence of uncapped end-groups which influences the cell activation (87). 
Smaller and less hydrophilic PLA and PLGA 752 particles may be efficiently internalized, but their surface characteristics may 
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not be able to activate the oxidative metabolism to an extent comparable to that of polymer surfaces containing specific 
functional groups, such as -COOH and -OH in the end-group of uncapped polymers (88). 
 
These results were corroborated in experiments performed with macrophages infected with Brucella. It was found that 
the effect of gentamicin-loaded PLGA 502H microparticles significantly decreased the intracellular bacterial levels of infected 
monocytes in comparison to PLGA 502 microparticles, although PLGA 502H released only 14% of the encapsulated gentamicin 
within the initial 24 h in vitro, as compared to a 50% burst release from the PLGA 502 microparticles (89). It can thus be 
hypothesized that a higher number of PLGA 502H particles were phagocytosed, increasing bactericidal oxidative burst that will 
act synergistically with gentamicin activity (48). 
 
Recently, this potential capacity of polymeric DDS to induce the activation status of the macrophages has also been 
confirmed by Sharma et al. in the case of PLA microparticles (90). In this study, the authors observed that microparticles 
containing two anti-tuberculosis agents, rifampicin and isoniazid, efficiently targeted lung macrophages and enhanced the 
respiratory burst and nitric oxide production by macrophages. The results showed significantly higher amounts of reactive 
nitrogen intermediates in M. tuberculosis-infected cells treated with inhalable microparticles in comparison to non-treated ones. 
Moreover, drug-containing microparticles induced the release of O2- and both TNF-alpha and IL-12 cytokines in contrast to 
unloaded microparticles.  
 
Taken together, these studies reveal that the ingestion of microparticles by macrophages may result in their activation 
and, subsequently, may enhance the host defense functions of the immune system. 
 
5.2.3. In vitro efficacy of polymeric particles for antibiotic treatment 
In vitro studies using infected macrophages have demonstrated that antibiotic-containing polymeric particles efficiently 
target phagocytic cells achieving therapeutic drug concentrations intracellularly and consequently improving the killing of 
intracellular microorganisms. PLGA microparticles containing gentamicin have been shown to enhance the intracellular killing of 
Brucella abortus (89) and Brucella melitensis (91) in infected macrophages. Prior et al. prepared gentamicin containing 
microparticles by the spray-drying method using PLGA 502 and PLGA 502H polymers (89). Treatment of the infected cells with 
gentamicin-loaded PLGA 502 and PLGA 502H microparticles reduced the infection by 1 and 2 log units, respectively, compared 
with untreated controls, whereas unloaded microparticles were not able to enhance the killing of bacteria. However, only the 
treatment with gentamicin PLGA 502H microparticles was significantly more effective in reducing bacteria than free gentamicin. 
Furthermore, in order to improve the dispersability of the particle the effect of the addition of 2% (w/v) of poloxamer 188 to the 
medium was studied. Interestingly, it was found that an increased antibacterial activity of microencapsulated gentamicin is 
achieved by dispersing the microparticles in this surfactant (3.5 log units for PLGA 502H microparticles). Although the 
mechanism responsible for this effect is still unclear, several factors may have played a role in this outcome. Surfactant 
adsorption onto the microparticles may have altered the surface polarity and subsequently enhanced cell adhesion and 
phagocytosis, which might have been additionally facilitated by a higher degree of particle dispersion in the presence of the 
surfactant. One can also speculate that unspecific cell activation by the surfactant and synergistic enhancement of the antibiotic 
activity could also have exerted some antibacterial effect. 
 
PLGA 502H microparticles prepared by the solvent evaporation method were further used against B. melitensis 
infected human macrophages (91). The results demonstrated that these PLGA microparticles are efficiently captured by the 
macrophages and that the gentamicin released from these particles is active and can exert its bactericidal effect inside the 
macrophagic cells. A 30 μg dose of encapsulated gentamicin reduced the intracellular Brucella counts by 2.2 log units. By using 
transmission electron microscopy and immunocytochemistry (gold-labeled antibodies against gentamicin), it was possible to 
observe the released of the antibiotic from the particles, not only in the cytoplasm and nucleus but also inside Brucella’s 
compartment (Figure 4). PLGA 502H nanoparticles were also prepared by this method, but even though they showed a higher 
capacity for monocyte activation than microparticles, they were discarded for in vitro efficacy studies due to the low antibiotic 
entrapment obtained (92).  
  
Another aminoglycoside, streptomycin, and the tetracycline doxycycline have also been encapsulated in polymeric 
nanoparticles and used against intracellular B. melitensis (93). The antibiotics were simultaneously incorporated in a PEO-b-
PtBA (poly(ethylene oxide)-b-poly(tert-butyl acrylate)) diblock copolymer and efficacy studies were performed in infected 
murine macrophages. Both the antibiotic combination containing nanoparticulated carriers and the free drugs completely 
eradicated the infection. Doxycycline has the ability to penetrate and concentrate into cells but, due to its mainly bacteriostatic 
activity for the treatment of brucellosis, it is used in combination with an aminoglycoside presenting bactericidal activity. In this 
case, the capability of the polymeric nanoparticles to enter cells and target intracellular B. melitensis was confirmed. Moreover, 
as discussed below, although there were no differences between the efficiency of free and encapsulated drugs in vitro, studies in 
vivo confirmed the advantage of using encapsulated gentamicin over free gentamicin (93). 
 
Encapsulation in polyisohexylcyanoacrylate (PIHCA) nanoparticles is a different well-studied strategy for the delivery 
of another antibiotic, ampicillin, to mouse macrophages (94). It has been observed by confocal micrographs and transmission 
electron microscopy that ampicillin-loaded PIHCA nanoparticles efficiently target Salmonella-infected murine macrophages. 
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Although at early stages, endocytic vesicles contained mainly intact nanoparticles, at later stages nanoparticles were localized in 
close contact with bacteria inside phagosomes and phagolysosomes. Moreover, ultrastructural autoradiography showed that, apart 
from increasing the penetration of the antibiotic into macrophages, ampicillin nanoparticles had increased bactericidal effect 
against Salmonella typhimurium, even at incubation times as short as 2-4 h (95).  
 
Ampicillin bound to PIHCA nanoparticles has also been studied in the same in vitro model of L. monocytogenes 
infection (96). In addition to the results obtained for Salmonella these nanoparticles were also effective regarding the treatment of 
L. monocytogenes-infected cells. After 30 h of incubation, nanoparticles reduced the number of viable bacteria by 1.75 log units 
over the free drug. However, in this case a lag period of 6-9 h was required for the antimicrobial effect to begin, probably due to 
the different intracellular localization of these bacteria. 
 
6. TREATMENT OF EXPERIMENTAL INFECTIONS MEDIATED BY DRUG DELIVERY SYSTEM 
 
6.1. Tuberculosis  
Tuberculosis is one of the leading causes of death worldwide with more than 3 million deaths annually. It is estimated 
that one-third of the world’s population is infected with Mycobacterium tuberculosis, the causative agent of tuberculosis, Asia 
and Africa being the continents with the highest annual incidence. Moreover, with the increased incidence of acquired 
immunodeficiency syndrome, tuberculosis has become a significant opportunistic disease.  
 
Current treatment of tuberculosis requires daily administration of multiple antitubercular drugs for at least 6 months. 
This prolonged and uncomfortable therapeutic schedule is the main reason for patient non-compliance and therefore for 
therapeutic failures and the emergence of multidrug resistant-tuberculosis.  
 
In this context, the development of a drug carrier that, with a single dose, could maintain therapeutically active levels of 
the drug for prolonged periods of time without causing any toxicity would be the ideal solution to tuberculosis treatment. Some 
of the most important achievements of the encapsulation of antitubercular drugs are the reduction of drug-associated toxicity, as 
well as the reduced dose and dosing frequency needed to achieve a therapeutic effect. The first objective of this DDS-mediated 
therapy is to achieve sustained therapeutic drug levels at the infection sites. In this sense, important improvements have been 
obtained. When administered as conventional formulations, rifampicin and isoniazid achieve low serum concentrations and are 
maintained in circulation for less than 24 h. Conversely, intravenous administration of 12 mg/kg and 10 mg/kg liposome-
entrapped isoniazid and rifampicin resulted in sustained therapeutic drug levels for up to 5 and 7 days in serum and organs 
respectively (97). This modification of the pharmacokinetics of these drugs may permit a weekly treatment regimen instead of the 
current daily one. Moreover, the chemotherapeutic efficacy of liposome-encapsulated isoniazid and rifampicin administered once 
a week has been demonstrated in a murine tuberculosis model. It was found that only one third of the dosage of isoniazid and 
rifampicin was necessary to achieve therapeutic effects when administered as a liposomal formulation.  
 
At equivalent doses, antibiotic-loaded liposomes were significantly more effective in reducing the number of bacteria 
in lungs, liver and spleen than the combination of free oral drugs. Besides, no sign of liposome-induced hepatotoxicity was 
observed during the treatment. Thus, this liposome-mediated treatment of tuberculosis may be a promising approach to obtain a 
therapy with good patient compliance, low cost and reduced dosage frequency and toxic effects. 
 
The encapsulation of antitubercular drugs in polymeric particles is another strategy to improve the current therapeutic 
regimen of tuberculosis. In the last few years several antitubercular drugs-containing PLGA and PLA microparticles and mainly 
nanoparticles have been exhaustively studied. One of the most novel proposals for the chemotherapy of tuberculosis is the use of 
inhalable or respirable particulate carriers that deliver antimycobacterial drugs directly in the lungs, thus achieving high drug 
concentration at the main infection site while reducing systemic toxicity. The pharmacokinetics and antimycobacterial effect of 
polymeric particles carrying antitubercular drugs have been studied in guinea pigs. Polymeric carriers have shown better 
pharmacokinetics profiles than liposomes. A single nebulization of rifampicin, isoniazid and pirazinamide coencapsulated in 
PLGA nanoparticles administered to guinea pigs maintained therapeutic drug concentrations in the plasma and lungs for 6 to 8 
days, and for up to 11 days, respectively (98). Moreover, great antimycobacterial activity was shown in the lungs of the animals 
treated with nanoparticles. The nebulization of the nanoparticulated formulation every 10 days resulted in the sterilization of the 
lungs after five doses. In contrast, 46 daily doses of orally administered drugs were required to achieve an equivalent therapeutic 
outcome. In this case, the superior efficacy of nanoparticulate systems over the microparticulated ones seems to be clear, as no 
inhalable microparticle formulation has been able to completely eradicate the lung infection (99, 100). 
 
Another interesting feature is that the stability of polymeric particles allows the possibility of an oral administration. 
Ul-Ain and co-workers demonstrated that PLGA microparticles provide a sustained release of isoniazid, rifampin and 
pyrazinamide for up to 9 days in various organs and for at least 3 days in plasma (101). In this case, weekly oral administration of 
nanoparticles showed similar results to those obtained by the daily-administration of free drugs. Moreover, the chemotherapeutic 
efficacy of PLGA-encapsulated drugs given orally was equivalent to that of subcutaneously injected drugs, but with the 
advantage of being a more comfortable administration route. Once again the same drugs rendered better results when 
encapsulated into nanoparticles versus microparticles. Following a single oral administration of these nanoparticles in mice, drug 
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levels could be detected in plasma for 6-9 days and in organs for 9–11 days. Further, a total of 5 doses of drug-loaded 
nanoparticles administered every 10 days to Mycobacterium tuberculosis-infected mice completely eradicated the bacteria on the 
infected tissues (102). Thus, these studies clearly document the efficacy of polymeric nanoparticle-based antituberculosis 
chemotherapy in experimental tuberculosis as an alternative to long-term treatment regimens. 
 
6.2. Brucellosis 
Human brucellosis is still a major health problem worldwide with more than 500,000 cases per year. While the endemic 
disease is limited to some areas of the Mediterranean basin and developing countries in Asia, Africa and Latin America, the 
current expansion of international travel increases the likelihood that the disease may be observed in any non-endemic area.. 
Brucellosis is a systemic infection that can involve any organ or tissue in the body. The onset may be acute with fever, sweats, 
fatigue, malaise and arthralgias, or even more insidiously, may develop over a period of weeks to months. Most relapses appear 
during the first six months after therapy with milder clinical findings than those usually observed at the initial episode of the 
disease, although some patients develop particularly insidious clinical relapses. 
 
The aim of any treatment for human brucellosis is to fight against the symptoms of the disease, reduce complications 
and, eventually, prevent relapses. However, since the complete eradication of the microorganisms is very difficult to achieve, 
synergistic or additive antibiotic combinations are required for prolonged periods of time to obtain satisfactory results.  
  
Although in the last two decades many trials have provided good evidence criteria for its antibiotic treatment, the most 
appropriate antimicrobial therapy for human brucellosis continues to be a controversial issue. Overall, the combination of oral 
doxycycline and intramuscular aminoglycosides is considered the most effective treatment, with an associated relapse rate of 5% 
(103). Significant drawbacks include the need for parenteral administration and the potential toxicity of aminoglycosides. The 
effective role of aminoglycosides in this combination should be stressed: whereas aminoglycosides used as monotherapy have 
shown little efficacy, probably due to their poor intracellular penetration, they have shown a substantial synergistic effect with 
tetracyclines in vitro and in vivo (104). The oral combination of doxycycline and rifampicin for 45 days is so far the best 
alternative treatment, because of its lack of side effects and its acceptability to patients. However, this treatment it is less effective 
(failure rate about 15%), mainly in the complicated forms of the disease (103). 
 
Thus, alternative methods such as DDS to achieve high intracellular bactericidal activity should be considered. The 
development of antibiotic-containing liposomes was the first approach to overcome the mentioned drawbacks and to obtain a 
more effective and compliable treatment for brucellosis. Vitas et al. designed a new method for the preparation of cationic SPLV 
loaded with gentamicin, which achieved a high removal of intracellular bacteria (57). Subsequent in vivo studies in mice infected 
with B. abortus concluded that these liposomes produce a fairly significant protective effect, not observed in antibiotic-free 
treatments or with negatively charged liposomes, demonstrating the efficacy of those newly developed liposomes in the treatment 
of brucellosis (105). However, despite the promising results described above, important drawbacks are attributed to these 
vesicles, such as their instability in the presence of blood lipoproteins and their osmotic fragility, which can destabilize them, 
leading to the leakage of the entrapped drug. In addition the long-term stability during storage of liposomes is also an unresolved 
problem. 
 
Therefore, several works with polymeric microparticles and nanoparticles were initiated. Prior et al. prepared PLGA 
502H microparticles by the spray-drying method. Vectors with a good encapsulation and release profile of gentamicin were 
obtained. In addition, the formulations activated macrophages (48) and significantly reduced the number of intracellular bacteria 
in vitro (89) Unfortunately the particles lacked therapeutic activity in vivo because, although their size was suitable for 
intravenous administration, these formulations showed a marked tendency to aggregate, resulting in poor circulation of the 
microparticles to the spleen, considered the target organ of Brucella.  
 
The particle aggregation was solved by using the emulsion formation/solvent evaporation method when formulating 
particles. In fact, Lecároz et al. showed that when administered in 502H micro or nanoparticles or 752H microparticles, 
gentamicin was successfully delivered to the liver and the spleen (85, 92). Pharmacokinetic parameters illustrated the markedly 
altered distribution of PLGA-loaded gentamicin compared to the free drug, as higher concentrations of the antibiotic in the spleen 
and liver were observed when it was administered loaded in microparticles. At the same time, undetectable concentrations were 
obtained in the serum samples, precluding drug accumulation in the kidneys. 
 
This long persistence of gentamicin beyond the half-life of the particles is probably a result of the nature of this 
aminoglycoside. These drugs are highly stable and are not metabolized in the liver. As a consequence, their intracellular retention 
is very high. 
 
Furthermore, when mice were chronically infected with a virulent strain of this bacterium and treated with both 
microparticle formulations, the level of infection in the spleen was significantly reduced after a single microparticle 
administration (1.45 log for 752H microparticles and 0.45 log for 502H microparticles, at 3 weeks post-treatment). In contrast, 
free gentamicin was ineffective. Distribution studies showed that after two weeks, only 752H microparticles remained intact in 
the spleen and, in modest quantities, in the liver. However, gentamicin was detected up to four weeks post-administration in both 
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spleen and liver after a single dose of administration of the microparticle formulations. These gentamicin concentrations were 
within the range of the in vitro MBC for Brucella, and consequently a significant reduction of the level of infection was observed 
in the spleen of mice chronically infected, 7 days after a single microparticle administration.  
 
Recently, polymeric nanoparticles prepared using PEO-b-PtBA diblock copolymer and carrying streptomycin and 
doxycycline have been developed for brucellosis treatment as alternative systems to PLGA copolymers (93). B. melitensis-
infected mice were treated with 9 mg/kg streptomycin and 1.8 mg/kg doxycycline, either free or incorporated in nanoparticles. 
After 3 days, both the free drugs and nanoparticles containing the drug combination had reduced the infection in the spleen (0.51 
log and 0.72 log reduction, respectively) but only the nanoparticles obtained a significant reduction of the infection in the liver 
(0.79 log reduction). Thus, alternative methods such as DDS to achieve high intracellular bactericidal activity seem promising. 
The possible use of drug delivery systems containing aminoglycosides may be one of the most relevant therapeutic advances in 
human brucellosis treatment in the recent years. 
 
6.3. Salmonellosis 
 Salmonellosis is one of the most serious food-borne diseases affecting humans. It may be considered the most 
important pandemic zoonosis under natural conditions. Salmonella spp. are facultative intracellular bacteria that can cause a wide 
spectrum of disease ranging from gastroenteritis, enteric fever, bacteremia and focal infections, to a chronic carrier state. 
Currently, the most important problems concerning treatment of salmonellosis are the emerging resistance to fluoroquinolones, 
the production of extended-spectrum beta-lactamases and the increase of multidrug resistant Salmonella strains.  
  
 Several studies using antibiotic-loaded nanoparticles have been performed in order to assess the suitability and efficacy 
of these carriers in experimental models of salmonellosis. PIHCA nanoparticles have shown promising results, reducing the 
mortality in acute infections caused by S. typhimurium in mice (106). A single dose of 0.8 mg encapsulated ampicillin resulted in 
the survival of all mice 60 days after bacterial inoculation. In contrast, 3 doses of 32 mg free ampicillin were required to obtain 
the same effect. All untreated mice and those treated with empty nanoparticles died within 10 days post infection. The authors 
attribute this enhanced effect to the selective targeting of the carriers to the infected tissues as well as to the effective intracellular 
targeting observed in vitro (94, 95). In order to assess whether polyalkycyanoacrylate nanoparticles were also effective against 
non-dividing bacteria, Page-Clisson et al. studied the effectiveness of these carriers in a model of persistent S. typhimurium 
infection (107). They found that although at early stages of the infection, when bacteria are actively dividing, there was an 
antibacterial effect, neither free nor nanoencapsulated ciprofloxacin or ampicillin could significantly reduce infection in the liver 
or the spleen at later stages. Therefore, the important role of the metabolic state of the bacteria on their susceptibility to 
antibiotics was again confirmed.  
 
 Ampicillin has also been entrapped in liposomes for the treatment of salmonellosis. As seen with nanoparticles, 
ampicillin-containing liposomes concentrate mainly in the spleen and at a lesser extent in the liver. However, liposomes were 
shown to be less effective for the treatment of acute S. typhimurium-induced samonellosis than PIHCA nanoparticles (108). A 
single dose of 0.8 mg liposome-bound ampicillin protected 60% of the treated mice in comparison with 100% protection 
achieved with nanoparticles (106). Moreover, the nanoparticles were more effective targeting ampicillin to the liver than 
liposomes. 
 
Apart from ampicillin, aminoglycoside-loaded liposomes have also been employed in the treatment of experimental 
salmonellosis. A 20 mg dose of liposome-entrapped streptomycin was shown to prolong survival of mice to at least one month. 
When 2 doses of 20 mg or a single dose of 80 mg were administered, the mice survived for more than 55 days (109). Moreover, 
the liposome entrapment of streptomycin markedly decreases its toxicity. Gentamicin is also more effective against S. 
typhimurium and S. dublin when it is administered bound to liposomes. 10 mg/kg liposomal gentamicin markedly enhanced the 
survival of S. typhimurium-infected BALB/c mice regardless of whether liposomes were administered a week prior or 1 or 2 days 
after infection (110). In the case of mice bearing a systemic S. dublin infection, the administration of 2, 10 and 20 mg gentamicin 
loaded into liposomes resulted in 80, 90 and 100% mice survival, respectively (111). pH-sensitive liposomes have also been 
successfully used for the treatment of S. typhimurium-infected mice (112). Gentamicin concentration in the liver and spleen were 
increased by 153- and 437-fold, respectively, when this drug was administered encapsulated into pH-sensitive liposomes. 
Moreover, the concentration of the antibiotic in the kidney was reduced 2.8 times. This favorable pharmacokinetic behavior was 
associated with an improved in vivo efficacy of the carriers. The administration of 0.2 to 5 mg/kg liposomes resulted in a 3 log 
reduction of the bacteria in the spleen, while the same doses were ineffective when administered as free drugs.  
 
Therefore, alternative methods such as DDS which achieve high protective and bactericidal activity should be taken 
into account in the future as suitable treatments for Salmonella-induced infections.   
 
6.4. Listeriosis 
 Listeriosis is a severe foodborne disease caused by the facultative intracellular pathogen, Listeria monocytogenes. This 
bacterium is an important cause of life-threatening infections, including sepsis and meningoencephalitis, especially in neonates, 
pregnant women, the elderly and immunocompromised patients. Additionally, although isolates of L. monocytogenes are 
susceptible to a wide range of antibiotics (35), the clinical management of listeriosis remains a difficult task due to the ability of 
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this microorganism to multiply intracellularly and spread cell-to-cell without leaving the protective environment of the host's 
cells. The current therapy of choice for listeriosis treatment is a combination of ampicillin and an aminoglycoside, usually 
gentamicin (113). 
 
 Different carriers of ampicillin have been developed in order to increase the antibiotic availability at the intracellular 
sites where the bacteria reside. Distribution studies in uninfected mice showed that when ampicillin was administered 
intravenously entrapped into liposomes, it quickly concentrated in the liver and mainly in the spleen (108). Moreover, the 
efficacy of liposomes and free antibiotic were assessed in Listeria-infected mice. Seven days after the treatment, ampicillin-
loaded liposomes had reduced the infection by 3.2 logs in the liver and 2.8 logs in the spleen, while free ampicillin was 
ineffective. In another study, Bakker-Woudenberg et al. also observed that higher concentrations of ampicillin were obtained in 
the liver when the antibiotic was administered bound to liposomes (71). Moreover, they found that the lipid composition of the 
carriers had a marked influence on the in vivo behaviour of the liposomes. For example, although less fluid liposomes maintained 
higher ampicillin concentration for a longer period of time in the liver, they were less effective in the killing of bacteria than 
more fluid liposomes.  
 
 Regarding nanoparticles, ampicillin-containing polymeric nanoparticles were also significantly more effective than free 
ampicillin in a chronic experimental listeriosis in athymic nude mice (114). Seven days after the treatment administration, 
ampicillin-bound nanoparticles completely eradicated the infection in the liver, while free ampicillin did not ensure liver 
sterilization during the 19 days that the experiment lasted, even with doses as high as 48 mg (this total dosage was divided into 
three doses of 16 mg/each). Regarding the spleen, the differences between these treatments were not so notorious, but the 
ampicillin-loaded nanoparticles significantly reduced the infection compared to the untreated group (2.1 log reduction), an effect 
only achieved when high doses of free ampicillin were used. 
 
7. CONCLUDING REMARKS AND PERSPECTIVES. 
 
Up to now, no antibiotic therapy has been reported to eradicate most intracellular bacteria such us Brucella or 
Mycobaterium. Moreover, a prolonged exposure to combined antibiotics are required to reduce the disease relapses down to 5-
15%. In this sense, DDS have an important role in the management of intracellular infections. As stated above, formulation of 
antimicrobials in DDS can reduce the side-effects of these drugs and increase patient compliance, thus saving money on health 
care delivery (115). In this setting, the potential use of DDS loaded with antibiotics may be one of the most relevant therapeutic 
advances in the treatment of intracellular bacterial diseases in recent years. Liposomes have shown good potential in improving 
the efficacy and tolerability of antibiotics of current use, however, problems concerning their stability during storage and 
administration require rigorous attention. On the other hand, polymeric particles, mainly nanoparticles, have emerged more 
recently as attractive carriers for the delivery of drugs to infected cells. Synthetic biodegradable and biocompatible polymers 
have been shown to be effective for encapsulating a great variety of antibiotics. Moreover, these polymeric particles strongly 
enhance phagocytosis and are suitable for intracellular delivery of antibacterial agents. Therefore, it is likely that soon after 
confirmation of the safety properties of these antibiotic-loaded DDS pilot studies in humans could be initiated.  
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Table 1. Main intracellular bacteria that survive within phagocytic cells 
Organism Type of parasite Subcellular localization pH Ref. 
Shigella spp. Facultative Cytosol ~6.5 (6) 
Listeria monocytogenes Facultative Cytosol ~6.5 (7) 
Legionella pneumophila Facultative Phagolysosomes, endoplasmic reticulum 5.6 (8) 
Clamydia spp. Strict Inclusions (nonacidified vacuoles) >6.0 (9) 
DDS against intracellular infections   
Mycobacterium 
tuberculosis 
Facultative Early endosomes 1ND (10) 
Mycobacterium bovis Facultative Early endosomes 5.5 (11) 
Mycobacterium avium Facultative Early endosomes (5.6-6.3) (12) 
Salmonella spp. Facultative Modified phagosome (Salmonella-containing vacuole) <4.5 (13) 
Ehrlichia chaffeensis Strict Early endosome ND (14) 
Brucella spp. Facultative Endoplamic reticulum  (15) 
Bartonella hesenlae Facultative Specialized nonendocytic membrane-bound vacuole ND (16) 
Afipia felis Facultative Unfused vacuoles ND (17) 
Coxiella burnetii Strict Phagolysosome ~5 (18) 
Yersinia pestis Facultative Phagolysosomes ND (19) 
Yersinia 
pseudotuberculosis 
Facultative Phagosomes 6.0 (20) 
Francisella tularensis Facultative Phagosomes 6.7 (21) 
Staphylococcus. aureus Facultative Phagolysosome ND (22) 
Abbreviations: 1ND = Not determined. 
 
Figure 1. Bacterial phagocytosis and phagolysosome biogenesis. In the endocytic pathway, internalized molecules are delivered 
to early endosomes, following recycling of part of this network of tubules and cisternae (containing receptors) back to the plasma 
membrane, whereas other components of the endosome are transported to late endosomes and lysosomes for degradation. On the 
other hand, phagocytosis and phagosome maturation are coordinated with the endocytic pathway through sequential activities of 
molecules that regulate the cytoskeleton and direct fusion and other contact events between components of the phagocytic and the 
endocytic pathways. Professional phagocytes enclose the adsorbed microorganism into membrane-bound organelles called 
phagosomes. Following internalization, this process leads to phagosome maduration as a sequential process involving fusion with 
components of the natural endocytic pathway (early endosomes, late endosomes and lysosomes), ultimately forming the 
phagolysosome. In the phagolysosome the ingested materials are finally degraded. Maturation in both endocytic and phagocytic 
pathways are also accompanied by changes in the vesicular markers content. Changes in the phospholipid composition are also 
observed during phagosome maturation. While early phagosomes are enriched with phosphatidylcholine, late phagosomes are 
preferentially enriched with sphingomyelin. 
 
Figure 2. Different intracellular fate of conventional and pH-sensitive liposomes. Conventional liposomes are delivered to 
lysosomes (LYS) and degraded, releasing the contained drug. pH-sensitive liposomes also traffic through early and late 
endosomes (EE and LE) to lysosomes, where they are unstable. At the acidic pH of lysosomes, these liposomes are able to 
destabilize the lysosomeal membrane or fuse to it, releasing their drug content into the cell cytoplasm.  
 
Figure 3. Intracellular trafficking of polymeric particles. The polymeric particle surface needs to stimulate binding to the cellular 
membrane to initiate phagocytosis. Two principal mechanisms have been discussed to explain the internalization of particles into 
cells: the zipper-like and the trigger-like mechanisms. In the zipper mechanism, pseudopods go forward to engulf particles, 
probably due to their high affinity toward the cell membrane, resulting in the formation of tightly apposed phagosomes. These 
events occur in the case of cationic or hydrophobic particles. In contrast, hydrophilic or anionic particles are phagocytosed 
without formation of pseudopods and end up in loosely apposed phagosomes. As a trigger mechanism, the particle would be 
ingested in a sinking-in-to-the-cell-like manner, in loose contact with the phagosomal membrane. Phagocytosis leads to the 
intracellular entrapment of particles in phagosomes, which mature under the influence of acidification, resulting from their fusion 
with lysosomes (LYS). The process of phagosome maturation has been shown to relate to the degree of apposition of the 
phagosomal membrane to the entrapped particle. -Hydrophobic particles tightly fitted in phagosomes inhibit maturation by 
resisting rapid fusion with lysosomes, because of the ionic interactions with the negatively charged phagosomal membrane. 
These particles are therefore found in relatively neutral microenvironments (6.0–6.8) and in tight apposition to the phagosomal 
membrane. -Hydrophilic particles, entrapped loosely in the phagosomes, are subjected to rapid fusion with lysosomes. These 
particles are then found in more acidic microenvironments typical of matured phagosomes (pH 4.6 to 5.1). Abbreviations: EE = 
early endosome; LE = late endosome.  
 
Figure 4. Transmission electron micrographs of THP-1 human monocyte engulfing both gentamicin-containing microparticles 
(MP) and Brucella melitensis cells (BM). White microparticles and dark brucellae can be seen throughout the monocyte. 
Microparticles ranged in size around 1.0 μm in diameter and appeared as discrete membrane-bound particles. Gentamicin was 
detected (immunogold dots) inside microparticles and also inside Brucella’s compartment. (Original magnification x 10.000). 
 
